Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'

被引：3
|
作者：
Dankner, Matthew [1 ,2 ]
Rose, April A. N. [3 ]
机构：
[1] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada
[2] McGill Univ, Dept Med, Montreal, PQ, Canada
[3] Univ Toronto, Dept Med, Div Med Oncol, Toronto, ON, Canada
来源：
BRITISH JOURNAL OF CANCER | 2018年 / 118卷 / 09期
关键词：
RAS MUTATIONS;
D O I：
10.1038/s41416-018-0012-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1276 / 1277
页数：2
相关论文
共 50 条
  • [41] Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies
    Dandan Cui
    Dan Cao
    Yu Yang
    Meng Qiu
    Ying Huang
    Cheng Yi
    Molecular Biology Reports, 2014, 41 : 1291 - 1298
  • [42] FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer
    Ying, Hou-Qun
    Wang, Feng
    Chen, Xiao-Lin
    He, Bang-Shun
    Pan, Yu-Qin
    Chen, Jie
    Liu, Xian
    Cao, Wei-Jun
    Peng, Hong-Xin
    Lin, Kang
    Wang, Shu-Kui
    ONCOTARGET, 2015, 6 (29) : 28071 - 28083
  • [43] Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer
    Lee, Michael Sangmin
    Lieu, Christopher Hanyoung
    Overman, Michael J.
    Eng, Cathy
    Morris, Jeffrey
    Jiang, Zhi-Qin
    Morelli, Maria
    Heymach, John
    Tran, Hai T.
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [44] Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies
    Cui, Dandan
    Cao, Dan
    Yang, Yu
    Qiu, Meng
    Huang, Ying
    Yi, Cheng
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1291 - 1298
  • [45] Safety and efficacy of modified schedula of anti-EGFR monoclonal antibodies plus chemotherapy as first line treatment in metastatic colorectal cancer patients
    Mancarella, S.
    Poti, O.
    De Giorgi, D.
    Schirinzi, M. L.
    De Maria, G.
    Rizzo, A.
    De Benedittis, A.
    Galante, M. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 52 - 52
  • [46] RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer
    Sunakawa, Yu
    Nakamura, Masato
    Ishizaki, Masahiro
    Kataoka, Masato
    Satake, Hironaga
    Kitazono, Masaki
    Yanagisawa, Hideyuki
    Kawamoto, Yasuyuki
    Kuramochi, Hidekazu
    Ohori, Hisatsugu
    Nakamura, Michio
    Maeda, Fumiyo
    Komeno, Chihiro
    Sonezaki, Tomoko
    Takeuchi, Masahiro
    Fujii, Masashi
    Yoshino, Takayuki
    Tsuji, Akihito
    Ichikawa, Wataru
    JCO PRECISION ONCOLOGY, 2020, 4 : 898 - 911
  • [47] Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study
    Cremolini, C.
    Morano, F.
    Moretto, R.
    Berenato, R.
    Tamborini, E.
    Perrone, F.
    Rossini, D.
    Gloghini, A.
    Busico, A.
    Zucchelli, G.
    Baratelli, C.
    Tamburini, E.
    Tampellini, M.
    Sensi, E.
    Fuca, G.
    Volpi, C.
    Milione, M.
    Di Maio, M.
    Fontanini, G.
    De Braud, F.
    Falcone, A.
    Pietrantonio, F.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3009 - 3014
  • [48] Comprehensive analysis of egfr and its downstream pathways deregulation identifies the vast majority of metastatic colorectal cancer (mCRC) patients resistant to anti-egfr monoclonal antibodies (MoAbs)
    Frattini, M.
    Molinari, F.
    De Dosso, S.
    Martin, V
    Crippa, S.
    Saletti, P.
    Mazzucchelli, L.
    VIRCHOWS ARCHIV, 2009, 455 : 46 - 46
  • [49] Continuing anti-EGFR monoclonal antibody after secondary resection significantly prolongs overall survival for patients with metastatic colorectal cancer who were responsive to first-line anti-EGFR monoclonal antibody plus chemotherapy doublet
    Hsieh, Yao-Yu
    Su, Yu-Li
    Kuan, Feng-Che
    Chen, Shu-Chuan Grace
    Chang, Chia-Lun
    Shao, Yu-Yun
    Tsai, Ching-Wen
    Liang, Yi-Hsin
    AMERICAN JOURNAL OF CANCER RESEARCH, 2024, 14 (12): : 5909 - 5920
  • [50] Preclinical Study of Adoptive Immunotherapy With Natural Killer Cells in Combination With Anti-EGFR Monoclonal Antibodies and Cytokines in Metastatic Colorectal Cancer
    Brugnatelli, S.
    Montagna, D.
    Turin, I.
    Manzoni, M.
    Castagna, L.
    Maestri, M.
    Grecchi, I.
    Santoro, A.
    Pedrazzoli, P.
    Todisco, E.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S436 - S436
12345